Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fadrozole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 15/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.97 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fadrozole SCHEMBL9739941 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL122801 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Dexfadrostat SCHEMBL4619633 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Dexfadrostat SCHEMBL685516 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| S-Fadrozole SCHEMBL13449014 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL25491 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL3295820 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL1650121 | 0.96 | CYP19A1 (0.95) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2351202 | 0.95 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Hydrochloric Acid SCHEMBL9836543 | 0.92 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12467 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2025-01-21 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | claimed |
| CN-118555971-A | Amorphous photosensitive particles, methods of making and methods of using the same | 马里兰大学帕克分校 | 2024-08-27 | — | — | CN | claimed |
| WO-2024162488-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CUCURBITACIN D FOR PREVENTING OR TREATING NEUROPATHIC PAIN | 주식회사 재인알앤피 | 2024-08-08 | — | — | WO | claimed |
| EP-4401780-A1 | AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF | University of Maryland, College Park (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2024026505-A2 | DISRUPTION OF TELOCYTE ACTIVITY | PATEL AMIT (US) | 2024-02-01 | — | — | WO | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| EP-0683237-B1 | METHOD OF EXAMINING HORMONE-DEPENDENT TUMOR | DAIICHI SEIYAKU CO (JP) | 2002-03-06 | — | — | EP | claimed |
| US-20010049349-A1 | Antioxidant enhancement of therapy for hyperproliferative conditions | CRABTREE ACQUISITION CO, LLC | 2001-12-06 | — | — | US | claimed |
| EP-1019034-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | Atherogenics, Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0683237-A1 | METHOD OF EXAMINING HORMONE-DEPENDENT TUMOR | SNOW BRAND MILK PRODUCTS CO., LTD. (JP) | 1995-11-22 | — | — | EP | claimed |
| EP-0437415-B1 | Crystalline form of the hydrochloride of 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)-benzonitrile | CIBA GEIGY AG (CH) | 1995-08-02 | — | — | EP | claimed |
| US-5162337-A | Administering Steroid Biosynthesis Inhibitors | MERCK & CO., INC. (US) | 1992-11-10 | — | — | US | claimed |
| EP-0437415-A2 | Crystalline form of the hydrochloride of 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)-benzonitrile | CIBA-GEIGY AG (CH) | 1991-07-17 | — | — | EP | claimed |